Desmoid Tumors Market - Opportunities, Share, Growth and Competitive Analysis and Forecast 2029

 This study helps professionals make sense of complex market trends and competitive shifts affecting the desmoid tumors industry today.

 

 How Big Is The Desmoid Tumors Market In 2025?
 The desmoid tumors market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.
 
 The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.
 
 Get your free sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13228&type=smp
 
 What Are The Major Factors Driving The Desmoid Tumors Global Market Growth?
 The rising cases of cancer are expected to propel the growth of the desmoid tumor market going forward. Cancer refers to a collection of disorders that are defined by the body’s aberrant cells growing and spreading out of control. These cells can infiltrate nearby tissues and organs and cause harm. The rising cancer cases worldwide have fueled the demand for effective and advanced chemotherapeutic agents, positively influencing the desmoid tumor market. For instance, in May 2024, according to National Cancer Institute, a US-based Federal government agency, In 2024, an estimated 2,001,140 new cases of cancer will be diagnosed in the U.S., with 611,720 deaths expected from the disease. In 2022, there were almost 20 million new cases and 9.7 million cancer-related deaths worldwide. By 2040, the number of new cancer cases per year is expected to rise to 29.9 million and the number of cancer-related deaths to 15.3 million. Therefore, the rising cases of cancer are driving the growth of the desmoid tumor market. 
 
 Desmoid Tumors Market Report Segmentation Analysis
 The desmoid tumorsmarket covered in this report is segmented — 
 
 1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
 2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
 3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
 
 Subsegments:
 1) By Surgery: Wide Excision; Minimally Invasive Surgery 
 2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy 
 3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids 
 4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors 
 5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy 
 6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies 
 7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies 
 
 What Are The Main Trends, Positively Impacting The Growth Of Desmoid Tumors Market?
 Major companies operating in the desmoid tumors market are developing innovative drugs such as nirogacestat for the treatment of desmoid tumors to meet the needs of their existing consumers better. Nirogacestat is an oral, small-molecule gamma-secretase inhibitor. For instance, in February 2023, SpringWorks Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, announced a U.S. Food and Drug Administration (FDA) acceptance and priority review of their new drug application (NDA) for nirogacestat for the treatment of adults with desmoid tumors. Nirogacestat is thought to work by blocking the production of notch proteins, which can lead to the death of tumor cells. Desmoid tumors produce high levels of notch protein, which is thought to contribute to their growth. Moreover, nirogacestat provides patients with a new treatment option that can potentially improve outcomes.
 
 What Are The Top Players Operating In The Desmoid Tumors Market?
 Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG 
 
 View the full desmoid tumors market report here:
 https://www.thebusinessresearchcompany.com/report/desmoid-tumors-global-market-report
 
 Which Region Holds The Largest Market Share In The Desmoid Tumors Market?
 North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company